适合移植的多发性骨髓瘤患者治疗研究进展  

Research progress of strategies for transplantation-eligible multiple myeloma patients

作　　者：郭欢[1] 陈文明[1] 

机构地区：[1]首都医科大学附属北京朝阳医院血液科,100020

出　　处：《白血病．淋巴瘤》2014年第9期564-566,共3页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81172252）;首都临床特色应用研究专项资助课题（Z131107002213146）

摘　　要：适合移植的多发性骨髓瘤（MM）患者的治疗通常采用三药方案诱导治疗后行造血干细胞采集.对于适合移植患者的标准预处理方案是大剂量美法仑方案.移植后行巩固治疗可提高缓解率.为了获得长期的疾病控制和改善总生存期,用硼替佐米或来那度胺（极高危患者二者联合）进行维持治疗是较合理的选择.随着新药在MM治疗中的应用,患者预后将会得到改善并获得长期的疾病控制.For transplantation-eligible multiple myeloma patients,induction treatment of triple drug regimens followed by the collection of hematopoietic stem cells is generally recommended.For transplantationeligible patients,high-dose melphalan remains the standard regimen.Consolidation after transplantation has shown an improvement in response rates.Maintenance therapy with bortezomib or lenalidomide （or both in very-high-risk patients） is a reasonable option for long-term disease control and improvement in overall survival.Application of new agents into therapy of multiple myeloma should result in improved outcomes and long-term disease control.

关 键 词：多发性骨髓瘤 治疗方案 造血干细胞移植 

分 类 号：R733.3[医药卫生—肿瘤]